Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
China Medical System/Tibet Kangzhe has a broad commercial portfolio with numerous exclusive licensed products in China. The company has successfully launched several innovative drugs such as diazepam nasal spray for seizures and tildrakizumab solution for injection. It also holds rights to various generics and specialty medicines across multiple therapeutic areas. The company continues to expand its R&D pipeline through partnerships and acquisitions of novel assets at different clinical stages.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Tibet Kangzhe Pharmaceutical Development.